Irritable bowel syndrome (IBS) is a common disorder that affects the abdominal organ, large intestine. It is also known as spastic colon, mucous colitis, irritable colon, and spastic colitis. The condition is much different than inflammatory bowel disease. However, it is a chronic condition which a person must manage for a longer period. It shows symptoms such as cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both at the same. These symptoms can be managed by changing stress, lifestyle, and diet. And the more severe symptoms are treated with medication and counseling.

According to our latest study on “Irritable Bowel Syndrome (IBS) Treatment Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Product, and Distribution Channel,” the market was valued at US$ 2,153.89 million in 2020 and is projected to reach US$ 4,600.30 million by 2028; it is expected to grow at a CAGR of 10.1% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.

Get sample PDF Copy of Irritable Bowel Syndrome (IBS) Treatment Market at @ https://www.theinsightpartners.com/sample/TIPRE00006814/

The healthcare sector witnessed SARS, H1N1, and other outbreaks in the past a few years. However, the severity of the COVID-19 outbreak has intensified due to its mode of transmission. North America has been witnessing an exponentially growing number of COVID-19 confirmed cases since its outbreak. The outbreak led to a chaotic situation in the medical industry across North American countries, leading to a dramatic rise in the demand for alternative medicines. The governments of various countries have been distributing the Irritable Bowel Syndrome (IBS) treatment medicines due to the rising COVID-19 cases. For instance, the Cuban government distributed homeopathic remedy PrevengHo-Vir to the geriatric and other vulnerable population. Therefore, Irritable Bowel Syndrome (IBS) treatment market is experiencing a positive impact of the COVID-19 pandemic owing to the rising demand for immunity booster medications.

The report segments global irritable bowel syndrome (IBS) treatment market as follows:

By Type                                                                                                                                              

·         IBS with Diarrhea (IBS-D)

·         IBS with Constipation (IBS-C)

·         Mixed IBS (IBS-M)

By Product

·         Rifaximin

·         Eluxadoline

·         Linaclotide

·         Lubiprostone

·         Others

By Distribution Channel

·         Hospitals Pharmacies

·         Drug Stores and Retail Pharmacies

·         Online Pharmacies

By Geography

·         North America

·         Europe

·         Asia Pacific (APAC)

·         Middle East & Africa (MEA)

·         South & Central America (SCAM)

Market leaders operating in the market have undertaken various organic growth strategies in the Irritable Bowel Syndrome (IBS) Treatment market. The Irritable Bowel Syndrome (IBS) Treatment market majorly consists of the players Ironwood Pharmaceuticals, Inc., AbbVie., Sebela Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Alfasigma S.p.A., Astellas Pharma Inc., AstraZeneca, Synthetic Biologics, Inc., Bausch + Lomb Incorporated and Lannett Company Inc. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have utilized organic strategies such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies including mergers & acquisitions, partnership, and collaborations.

For more details visit here @ https://www.theinsightpartners.com/reports/irritable-bowel-syndrome-treatment-market

Market leaders are involved in inorganic ways of business expansion such as merger & acquisitions and joint alliances, which have promoted its growth. For instance, in February 2018, Corning and CytoSMART agreed. CytoSMART is a Dutch company that deals with the automation of the laboratory process. This agreement is done to simplify the counting of mammalian cells in laboratories worldwide. As cell counting is a critical step in the cell culture workflow, this strategic collaboration has helped Corning to improve its products and services to its customers.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi

E-mail: sales@theinsightpartners.com

Phone: +1-646-491-9876